Your browser doesn't support javascript.
loading
Generation of JC Polyoma Pseudovirus for High-Throughput Measurement of Neutralizing Antibodies.
Matsuda, Mami; Li, Tian-Cheng; Nakanishi, Akira; Nakamichi, Kazuo; Saito, Makoto; Suzuki, Tadaki; Matsuura, Tomokazu; Muramatsu, Masamichi; Suzuki, Tetsuro; Miura, Yoshiharu; Suzuki, Ryosuke.
Afiliação
  • Matsuda M; Department of Virology II, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Li TC; Department of Virology II, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Nakanishi A; Department of Genetic Engineering, Kindai University, Wakayama 649-6493, Japan.
  • Nakamichi K; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Saito M; Clinical Research Support Center, Tokyo Metropolitan Komagome Hospital, Tokyo 113-8677, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Matsuura T; Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
  • Muramatsu M; Department of Virology II, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Suzuki T; Department of Infectious Disease Research, Foundation for Biomedical Research and Innovation at Kobe, Kobe 650-0047, Japan.
  • Miura Y; Department of Microbiology and Immunology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
  • Suzuki R; Department of Neurology, PML/MS/NMO Center, Tokyo Metropolitan Komagome Hospital, Tokyo 113-8677, Japan.
Diagnostics (Basel) ; 14(3)2024 Jan 31.
Article em En | MEDLINE | ID: mdl-38337826
ABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system (CNS) caused by reactivation of dormant JC polyomavirus (JCPyV). PML was mainly observed in immunocompromised individuals, such as HIV-positive patients, autoimmune disease patients, and cancer patients. Given that the presence of anti-JCPyV antibodies in serum is a risk indicator for PML development, it is essential to monitor anti-JCPyV antibody levels. In the present study, we established reporter-based single-infection neutralization assays for JCPyV and the genetically similar BK polyoma virus (BKPyV). We then confirmed the lack of cross-reactivity between the two viruses using test sera obtained from mice immunized with plasmids encoding the JCPyV or BKPyV capsid. Next, we compared neutralization antibody titers in sera from healthy donors, patients with multiple sclerosis (MS), and HIV-positive patients using an in-house enzyme-linked immunosorbent assay (ELISA) with JCPyV-like particles (virus-like particles; VLPs). A positive correlation was demonstrated between the neutralization titer (75% infectious concentration; IC75) against JCPyV and the antibody titer obtained by VLP-based JCPyV ELISA. This assay system may be applied to detect antibodies against other PyVs by generation of pseudoviruses using the respective capsid expression plasmids, and is expected to contribute to the surveillance of PyV as well as basic research on these viruses.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão